Bank of Montreal
PTGX icon

Bank of Montreal’s Protagonist Therapeutics PTGX Stock Holding History

Bank of Montreal’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$754K Buy
6,147
+390
+7% +$40.7K ﹤0.01% 2238
2026
Q1 		$607K Buy
5,757
+1,949
+51% +$173K ﹤0.01% 2300
2025
Q4 		$332K Sell
3,808
-56
-1% -$4.58K ﹤0.01% 2527
2025
Q3 		$257K Sell
3,864
-5,714
-60% -$325K ﹤0.01% 2619
2025
Q2 		$533K Buy
9,578
+642
+7% +$30.8K ﹤0.01% 2240
2025
Q1 		$432K Buy
8,936
+2,686
+43% +$113K ﹤0.01% 2282
2024
Q4 		$241K Buy
6,250
+270
+5% +$11.8K ﹤0.01% 2669
2024
Q3 		$266K Buy
+5,980
New +$242K ﹤0.01% 2856
2023
Q3 		– Sell
-310,000
Closed -$8.68M – 4136
2023
Q2 		$8.68M Buy
+310,000
New +$7.76M ﹤0.01% 1068
2022
Q1 		– Sell
-21,400
Closed -$734K – 4261
2021
Q4 		$734K Sell
21,400
-405
-2% -$12.8K ﹤0.01% 2140
2021
Q3 		$385K Sell
21,805
-42,475
-66% -$1.81M ﹤0.01% 3016
2021
Q2 		$2.84M Sell
64,280
-25,793
-29% -$851K ﹤0.01% 1878
2021
Q1 		$2.4M Sell
90,073
-43,501
-33% -$1.1M ﹤0.01% 1697
2020
Q4 		$2.75M Buy
133,574
+132,169
+9,407% +$2.84M ﹤0.01% 1682
2020
Q3 		$30K Sell
1,405
-400
-22% -$7.51K ﹤0.01% 3643
2020
Q2 		$32K Buy
1,805
+1,196
+196% +$15K ﹤0.01% 3637
2020
Q1 		$4K Sell
609
-2,185
-78% -$16.4K ﹤0.01% 3734
2019
Q4 		$19K Buy
2,794
+724
+35% +$7.19K ﹤0.01% 4343
2019
Q3 		$25K Sell
2,070
-753
-27% -$9.49K ﹤0.01% 3971
2019
Q2 		$34K Sell
2,823
-8,203
-74% -$90.7K ﹤0.01% 3873
2019
Q1 		$139K Buy
11,026
+10,405
+1,676% +$91.8K ﹤0.01% 2918
2018
Q4 		$4K Buy
621
+3
+0.5% +$24 ﹤0.01% 4180
2018
Q3 		$6K Buy
618
+9
+1% +$77 ﹤0.01% 4078
2018
Q2 		$4K Sell
609
-514
-46% -$3.95K ﹤0.01% 4187
2018
Q1 		$10K Sell
1,123
-4,807
-81% -$90.5K ﹤0.01% 3766
2017
Q4 		$123K Buy
5,930
+5,430
+1,086% +$96.3K ﹤0.01% 2919
2017
Q3 		$9K Sell
500
-24
-5% -$332 ﹤0.01% 3731
2017
Q2 		$6K Buy
+524
New +$5.6K ﹤0.01% 3841

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of Montreal's PTGX Position: Q2 2026 in Review

Bank of Montreal increased its Protagonist Therapeutics (PTGX) stake by 6.8% in Q2 2026, buying an estimated $40.7K and bringing the position to 6,147 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Bank of Montreal first reported a position in PTGX in Q2 2017 and has held it in 28 quarters since. The position peaked at $8.68M in Q2 2023. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Bank of Montreal held 6,147 shares of Protagonist Therapeutics worth $754K as of Q2 2026.
  • Bank of Montreal bought 390 Protagonist Therapeutics shares in Q2 2026, an estimated $40.7K.
  • Protagonist Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2238 holding.
  • Bank of Montreal first reported a position in Protagonist Therapeutics in Q2 2017 and has held it in 28 quarters since.
  • Bank of Montreal's Protagonist Therapeutics position peaked at $8.68M in Q2 2023.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.